MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Status:	Recruiting
Healthy:	No
Age Range:	18 - Any
Updated:	12/6/2018
Start Date:	March 22, 2018
End Date:	July 2021
Contact:	Medical Director Molecular Partners
Email:	info@molecularpartners.com
Phone:	+41 44 755 7700

A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib

The purpose of this study is to assess the anti-tumor efficacy, safety, tolerability,
pharmacokinetics (PK), immunogenicity and biological activity of the MP0250 DARPin® drug
candidate in combination with osimertinib orally once daily (o.d.), when administered to
patients with EGFR mutated, advanced, non squamous NSCLC after tumor progression on
osimertinib and on or after the most recent therapy.

MP0250 is a multi-DARPin® protein with three specificities, able to simultaneously neutralize
the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor
(HGF) and also to bind to human serum albumin (HSA) to give an increased plasma half-life and
potentially enhanced tumor penetration.

Inclusion Criteria:

1. Histologically confirmed metastatic or unresectable locally advanced non-squamous
NSCLC with documented EGFR mutation-positive disease

2. Radiologically documented disease progression on previous osimertinib treatment.

3. Radiologically documented disease progression on or after most recent antitumor
therapy.

4. Measurable disease according to RECIST 1.1.

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 2.

6. Men and women ≥18 years old on the day of signing informed consent.

7. Adequate hematological, hepatic and renal function prior to first dose

8. Serum albumin concentration ≥30 g/L

9. Potassium and magnesium within normal range

Exclusion Criteria:

1. Necrotic tumors or tumors close to large blood vessels that may impose an increased
bleeding risk when treated with anti-VEGF agents.

2. Second malignancy that is currently clinically significant or required active
intervention during the period of 12 months prior to Screening, except early stage
non-melanoma skin cancer treated with curative intent.

3. Known pre-existing interstitial or inflammatory lung disease.

4. Clinical signs of or documented leptomeningeal carcinomatosis. Features such as
headache, nuchal rigidity, and photophobia may indicate meningeal involvement.

5. Known brain metastases who are clinically unstable

6. Prohibited anti-NSCLC therapies and not having recovered from related AEs to Common
Terminology Criteria for Adverse Events (CTCAE) Grade ≤1

7. Any investigational drug within 28 days prior to study treatment.

8. Current participation in any other interventional clinical study (except survival
follow up).

9. Neuropathy as residual toxicity after prior antitumor therapy Grade >2

10. Patients taking medications that have the potential to prolong the QT interval

11. Significant cardiac abnormalities

12. Uncontrolled hypertension

13. Significant risk for bleeding

14. Active or recent thrombolic events

We found this trial at

sites

Florida Hospital

601 E Rollins St
Orlando, Florida 32803

(407) 303-5600